



31st March, 2016

To, The Manager, Listing Department, National Stock Exchange of India Ltd. "Exchange Plaza", C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.	To, Department of Corporate Services Bombay Stock Exchange Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.
Ref. : (i) Symbol – DISHMAN (ii) Series – EQ	Ref. : Scrip Code No. : 532526

Sub. Announcement - Regulation 30 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

Dishman is pleased to inform that Company has acquired further 50% stake in Schutz Dishman Biotech Ltd., a Joint Venture Indian Company, from the existing JV Partner i.e. SCHUTZ & CO. BETEILIGUNGSGESELLSCHAFT MBH, Germany for a consideration of EURO 300,000.

Schutz Dishman Biotech Ltd. ("Schutz Dishman"), is engaged in the business of manufacturing of Bulk Drugs, Drug formulations and performance Chemicals in India for export markets. Its plant is USFDA approved and is located in the existing campus of Dishman's Bavla manufacturing facility. The said acquisition will help the company in backward integration for some of its existing products and for manufacturing other APIs. Presently, Company is holding 22.33% stake in Schutz Dishman and after acquisition of further 50% stake, Schutz Dishman will become subsidiary of the Company.

Kindly take this on your record and acknowledge the receipt.

Thanking you.

Yours faithfully,
For Dishman Pharmaceuticals and Chemicals Limited


Pinaz H. Pithadia
Compliance Officer

Dishman Pharmaceuticals and Chemicals Limited

Registered Office: Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad – 380 009 India.

Tel: +91 (0) 79 26443053 / 26445807 Fax: +91 (0) 79 26420198

Email: dishman@dishmangroup.com Web: www.dishmangroup.com

Government Recognised Export House

CIN NO L24230GJ1983PLC006329